Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.

Q1 Biochemistry, Genetics and Molecular Biology

Current Pharmacology Reports Pub Date : 2021-01-01 Epub Date: 2021-02-18 DOI:10.1007/s40495-021-00253-w

Shivani Sood, Gurpreet Kaur Bhatia, Prachi Seth, Pawan Kumar, Jagjit Kaur, Vidisha Gupta, Sandeep Punia, Hardeep Singh Tuli

{"title":"Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.","authors":"Shivani Sood, Gurpreet Kaur Bhatia, Prachi Seth, Pawan Kumar, Jagjit Kaur, Vidisha Gupta, Sandeep Punia, Hardeep Singh Tuli","doi":"10.1007/s40495-021-00253-w","DOIUrl":null,"url":null,"abstract":"Purpose of review: The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.Recent findings: The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.Summary: The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 2","pages":"49-54"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00253-w","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40495-021-00253-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 13

Abstract

Purpose of review: The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.

Recent findings: The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.

Summary: The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019.

Abstract Image

查看原文本刊更多论文

新冠肺炎新药的疗效和安全性:法匹拉韦和地塞米松。

2019年严重急性呼吸综合征冠状病毒(sars - cov -2)广泛传播的呼吸道疾病已感染200多个国家，在世界范围内造成大流行和破坏。最新发现:对病毒基因组进行了快速测序，以研究其机制、流行病学、药物和疫苗。研究人员正在研究许多药物和疫苗来治疗和预防SARS-CoV-2。法匹拉韦和地塞米松是对SARS-CoV-2表现出治疗潜力和药物疗效的改型药物。摘要:综述了法匹拉韦和地塞米松抗SARS-CoV-2从化学作用到作用机制的作用路径。此外，还总结了潜在的副作用，研究其控制2019冠状病毒的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pharmacology Reports Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

9.30

自引率

0.00%

发文量

期刊介绍： Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development.provide incisive, insightful, and balanced contributions from international leading experts.interest a wide readership of basic scientists and translational investigators in academia and in industry. The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others. Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule.Please submit here: https://www.editorialmanager.com/phar/default.aspx